- Erratum
-
- KMID: 2515939
- J Korean Med Assoc.
- 2021 May;64(5):391-391.
- doi: 10.5124/jkma.2021.64.5.391
-
- CITED
-
- Close
- SHARE
-
- Close
- Practical strategies for the improvement of the Korean Medical Association’s governance
-
Kim JS, Lim JY
- KMID: 2515938
- J Korean Med Assoc.
- 2021 May;64(5):386-390.
- doi: 10.5124/jkma.2021.64.5.386
This study aims to suggest practical strategies for improving the governance system of the Korean Medical Association (KMA). To this end, we used survey studies, statistical analysis, and literature reviews.... -
- CITED
-
- Close
- SHARE
-
- Close
- Current advances in pharmacological treatments for patients with COVID-19
-
Kim SB, Yeom JS
- KMID: 2515937
- J Korean Med Assoc.
- 2021 May;64(5):375-385.
- doi: 10.5124/jkma.2021.64.5.375
Since the coronavirus disease 2019 (COVID-19) outbreak, more than 150 million people in over 200 countries have been infected, with over 3 million people dying due to it, as of... -
- CITED
-
- Close
- SHARE
-
- Close
- Gastrointestinal cancer treatment with immune checkpoint inhibitors
-
Kim JW
- KMID: 2515933
- J Korean Med Assoc.
- 2021 May;64(5):342-348.
- doi: 10.5124/jkma.2021.64.5.342
Immuno-oncological treatment approaches, particularly with the use of immune checkpoint inhibitors such as antiprogrammed death 1 (PD-1)/programmed death ligand 1 antibody or anti-cytotoxic T-lymphocyte associated protein 4 antibody, have become... -
- CITED
-
- Close
- SHARE
-
- Close
- Current status of cancer immunotherapy with immune checkpoint inhibitors
-
Lee MA
- KMID: 2515931
- J Korean Med Assoc.
- 2021 May;64(5):326-331.
- doi: 10.5124/jkma.2021.64.5.326
The clinical outcome in advanced cancer has improved since the development of targeted therapies and immune checkpoint inhibitors. We can expect better overall survival after a combination treatment with these... -
- CITED
-
- Close
- SHARE
-
- Close
- Treatment of advanced urogenital cancers with immune checkpoint inhibitors
-
Jung EH, Kim SH
- KMID: 2515934
- J Korean Med Assoc.
- 2021 May;64(5):349-357.
- doi: 10.5124/jkma.2021.64.5.349
The development of immune checkpoint inhibitors has improved the long-term survival of patients with several types of cancers, including bladder and renal cell carcinomas. Atezolizumab, an anti-programmed death-ligand 1 monoclonal... -
- CITED
-
- Close
- SHARE
-
- Close
- Rehabilitation therapy for patients with osteoporosis
-
Kim DH
- KMID: 2515936
- J Korean Med Assoc.
- 2021 May;64(5):366-372.
- doi: 10.5124/jkma.2021.64.5.366
Fractures in patients with osteoporosis are attributable to falls and reduced bone mass. Therefore, balance and muscle strength should be improved and bone mass should be increased to prevent fractures.... -
- CITED
-
- Close
- SHARE
-
- Close
- Management of adverse events in cancer treatment with immune checkpoint inhibitors
-
Kang MJ
- KMID: 2515935
- J Korean Med Assoc.
- 2021 May;64(5):358-365.
- doi: 10.5124/jkma.2021.64.5.358
The use of immune checkpoint inhibitors is associated with a spectrum of immune-related adverse events related to the mechanism of action which is quite different from that of cytotoxic chemotherapy.... -
- CITED
-
- Close
- SHARE
-
- Close
- Current advances in the treatment of lung cancer with immune checkpoint inhibitors
-
Lee GW
- KMID: 2515932
- J Korean Med Assoc.
- 2021 May;64(5):333-341.
- doi: 10.5124/jkma.2021.64.5.333
Lung cancer is the leading cause of cancer-related deaths worldwide despite major advances in platinum-based chemotherapy and targeted therapy based on activating driving mutations. Immune checkpoint inhibitors (ICIs) have revolutionized... -
- CITED
-
- Close
- SHARE
-
- Close
